Navigation Links
Hitting target in cancer fight now easier with new nanoparticle platform, UCLA scientists say
Date:5/4/2011

features employed by the UCLA research team include the manipulation of the size and surface properties of the nanoparticle to improve tumor biodistribution and protected delivery. The study demonstrates how, through an iterative design process, the first-generation MSNP was redesigned and optimized to deliver doxorubicin to a cancer xenograft in a mouse model.

The team demonstrated a significant increase in particle retention at the tumor site: Approximately 10 to 12 percent of all the drug-loaded particles injected intravenously reached the tumor site. This high tumor distribution is exceptionally good, compared with other polymer- and copolymer-based nanodelivery platforms for which the best passive tumor targeting is in the range of 3.5 to 10 percent of injected particles, the researchers said.

The study also demonstrated efficient drug delivery and tumor cellkilling using the redesigned and optimized MSNP system in mice.

"The amount of doxorubicin being delivered to the tumor site was considerably higher than what could be achieved by the free drug, in addition to allowing efficient delivery into the cancer cells at the tumor site," said Nel, who is also a member of UCLA's Jonsson Comprehensive Cancer Center.

Moreover, the improved drug delivery was accompanied by a significant reduction in systemic side effects such as weight loss and reduced liver and renal injury.

"This is an important demonstration of how the optimal design of the MSNP platform can achieve better drug delivery in vivo," Nel said. "This delivery platform allows effective and protective packaging of hydrophobic and charged anticancer drugs for controlled and on-demand delivery. Not only are these design features superior to induce tumor shrinkage and apoptosis compared to the free drug, but they also dramatically improve the safety profile of systemic doxorubicin delivery."


'/>"/>

Contact: Jennifer Marcus
jmarcus@cnsi.ucla.edu
310-267-4839
University of California - Los Angeles
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study shows hunger hitting closer to home
2. Chances of hurricane hitting Texas discussed at UH conference
3. How your body clock avoids hitting the snooze button
4. Why the swamp sparrow is hitting the high notes
5. MIT: Removable cloak for nanoparticles helps them target tumors
6. System in brain -- target of class of diabetes drugs -- linked to weight gain
7. La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders
8. Lesser-known Escherichia coli types targeted in food safety research
9. Target for lung cancer chemoprevention identified
10. Short rotation energy crops could help meet UKs renewable energy targets
11. Study identifies promising target for AIDS vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... of the sun could be available for the treatment of advanced ... seen whether the drug will be the revolution in prostate cancer ... is based on vitamin D and is given to patients in ... Drug makers came up with the idea because vitamin D from ...
... is the impressive result of a study carried out by ... Simoni of the Mario Negri Institute in Milan, Italy in ... of Lausanne. The study appears in the April 18th issue ... Library of Science, PLoS ONE. , Stroke is the first ...
... ecologists from the Centre of Environment and Hydrology (CEH) ... butterfly whose caterpillars live as parasites inside colonies of ... nurse ants. One of the peculiar features of this ... caterpillars complete development within one year. The rest are ...
Cached Biology News:Sunshine pill for prostate cancer in 2009 2Some caterpillers just don't want to grow up 2
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
(Date:7/1/2015)... ... 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker provided ... , The presentation took place on Tuesday, June 16 and provided an update on ... for the treatment of pancreatic cancer. A copy of the company overview can ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to take part in the first half of “Integrative Biotechnology,” an applied biotechnology ... established in summer 2014, this course combines students from both universities and is ...
(Date:6/30/2015)... -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a specialty ... unmet medical needs in women,s health, today announced ... at the Cantor Fitzgerald Inaugural Healthcare Conference as ... PM EDTLocation: , Le Parker Meridien Hotel, New ... under  ,Investor, or  click here The ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... , EAST NORRITON, Pa. , Aug. 2 Tengion ... has appointed A. Brian Davis to the position of Chief ... Technologies, Inc., a biopharmaceutical company using enzymatic technologies to develop improved protein ... and research personnel at three sites.  , ...
... 2 Reportlinker.com announces that a new market research report is available in ... Asia Pacific Flexible ... , ... This research service ...
... represents one of the most fundamental processes in physics. ... in the summer due to the absorption of light ... or light-emitting diodes that convert electricity into light, we ... lives. Understanding the interactions between individual light particles ...
Cached Biology Technology:Tengion Appoints A. Brian Davis Chief Financial Officer 2Asia Pacific Flexible Alternating Current Transmission Equipment Markets 2Asia Pacific Flexible Alternating Current Transmission Equipment Markets 3Asia Pacific Flexible Alternating Current Transmission Equipment Markets 4Asia Pacific Flexible Alternating Current Transmission Equipment Markets 5Asia Pacific Flexible Alternating Current Transmission Equipment Markets 6Asia Pacific Flexible Alternating Current Transmission Equipment Markets 7One more step on the path to quantum computers 2
...
...
...
... volume pipetting is increasingly essential for ... DNA sequencing and other biochemical applications. ... and precision unparalleled in the industry. ... of all aspirated,and dispensed volumes , ...
Biology Products: